Trials / Completed
CompletedNCT00759837
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Bosutinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics of bosutinib and the safety and tolerability of bosutinib in healthy subjects and subjects with liver disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bosutinib |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2008-09-25
- Last updated
- 2009-07-16
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT00759837. Inclusion in this directory is not an endorsement.